{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:59:30Z","timestamp":1789390770190,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.bcmd.2005.12.031","type":"journal-article","created":{"date-parts":[[2006,3,25]],"date-time":"2006-03-25T07:51:09Z","timestamp":1143273069000},"page":"379-384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Thrombotic complications in essential thrombocythemia (ET): Clinical facts and biochemical riddles"],"prefix":"10.1016","volume":"36","author":[{"given":"Petro E.","family":"Petrides","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2005.12.031_bib1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/BF01741104","article-title":"\u00dcber einen Fall von hochgradiger Throm-bozytenvermehrung","volume":"9","author":"Epstein","year":"1930","journal-title":"Klin. Wochenschr."},{"key":"10.1016\/j.bcmd.2005.12.031_bib2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMra035363","article-title":"Thrombocytosis","volume":"350","author":"Schafer","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2005.12.031_bib3","series-title":"Molecular Basis of Chronic Myeloproliferative Disorders","first-page":"65","article-title":"Growth factor signaling in polycythemia vera cells: specific hypersensitivities to cytokines in the chronic myeloproliferative disorders","author":"Axelrad","year":"2004"},{"key":"10.1016\/j.bcmd.2005.12.031_bib4","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2005.12.031_bib5","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.bcmd.2005.12.031_bib6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0002-9343(90)90491-U","article-title":"Hemostatic complications in young patients with essential thrombocythemia","volume":"88","author":"Mitus","year":"1990","journal-title":"Am. J. Med."},{"issue":"2 Suppl. 3","key":"10.1016\/j.bcmd.2005.12.031_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminhematol.2004.02.008","article-title":"Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders","volume":"41","author":"Kessler","year":"2004","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib9","first-page":"149","article-title":"Prevalence of specific thrombotic accidents in patients with thrombocytosis","volume":"25","author":"Randi","year":"1993","journal-title":"Haematologia"},{"key":"10.1016\/j.bcmd.2005.12.031_bib10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ajcp\/84.2.180","article-title":"Acute thrombotic complications of myeloproliferative disorders in young adults","volume":"84","author":"Davis","year":"1985","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib11","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/0277-5379(83)90091-3","article-title":"Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function","volume":"19","author":"Barbui","year":"1983","journal-title":"Eur. J. Cancer Clin. Oncol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib12","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2141.2005.05490.x","article-title":"Relevance of the criteria commonly used to diagnose myeloproliferative disorders in patients with splanchnic vein thrombosis","volume":"129","author":"Chait","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib13","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1002\/1097-0142(19910601)67:11<2926::AID-CNCR2820671136>3.0.CO;2-3","article-title":"Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients","volume":"67","author":"Colombi","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2005.12.031_bib14","doi-asserted-by":"crossref","unstructured":"J.J. Michiels, Z. Berneman, W. Schroyens, P.J. Koudstaal, J. Lindemans, H.H.D.M. van Vliet, Platelet-mediated thrombotic complications in patients with ET: reversal by aspirin, platelet reduction, and not by coumadin, Blood Cells, Mol. Dis. doi:10.1016\/j.bcmd.2005.12.021.","DOI":"10.1016\/j.bcmd.2005.12.021"},{"key":"10.1016\/j.bcmd.2005.12.031_bib15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1517\/14656566.5.5.1009","article-title":"Essential thrombocythemia in children: is a treatment needed?","volume":"5","author":"Randi","year":"2004","journal-title":"Exp. Opin. Pharmacother."},{"key":"10.1016\/j.bcmd.2005.12.031_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/(SICI)1096-8652(199711)56:3<168::AID-AJH6>3.0.CO;2-W","article-title":"Thrombotic complications in essential thrombocythemia with relatively low platelet counts","volume":"56","author":"Regev","year":"1997","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1365-2141.1997.d01-2127.x","article-title":"Prevention and treatment of thrombotic complications in ET: efficacy and safety of aspirin","volume":"97","author":"van Genderen","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib18","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.revmed.2005.02.006","article-title":"Pharmacogenetics and antiplatelet drugs","volume":"26","author":"Fontana","year":"2004","journal-title":"Rev. Med. Interne"},{"key":"10.1016\/j.bcmd.2005.12.031_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/(SICI)1096-8652(199804)57:4<277::AID-AJH2>3.0.CO;2-R","article-title":"Aspirin increases the bleeding side effects in essential thrombocythemia independent of the cyclooxygenase pathway: role of the lipoxygenase pathway","volume":"57","author":"Cortelazzo","year":"1998","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib20","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1002\/cncr.20646","article-title":"Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile","volume":"101","author":"Steurer","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bcmd.2005.12.031_bib21","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199504273321704","article-title":"Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis","volume":"332","author":"Cortelazzo","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2005.12.031_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10375","article-title":"Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea or hydroxyurea after busulfan","volume":"74","author":"Nielsen","year":"2003","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib23","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1517\/14656566.5.8.1781","article-title":"Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia","volume":"5","author":"Petrides","year":"2004","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.bcmd.2005.12.031_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/1040-8428(94)00164-O","article-title":"Bleeding and thrombosis in myeloproliferative disorders: mechanism and treatment","volume":"20","author":"Landolfi","year":"1995","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1055\/s-2007-996114","article-title":"Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders","volume":"23","author":"Wehmeier","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.bcmd.2005.12.031_bib26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1055\/s-2007-996125","article-title":"Microvascular disturbances, thrombosis, and bleeding in thrombocythemia: current concepts and perspectives","volume":"23","author":"Ravandi-Kashani","year":"1997","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.bcmd.2005.12.031_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V64.1.1.1","article-title":"Bleeding and thrombosis in the myeloproliferative disorders","volume":"64","author":"Schafer","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2005.12.031_bib28","series-title":"Molecular Basis of Chronic Myeloproliferative Disorders","first-page":"15","article-title":"Chronic myeloproliferative disorders: a pathologist's view","author":"Thiele","year":"2004"},{"key":"10.1016\/j.bcmd.2005.12.031_bib29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/jcp.39.2.129","article-title":"Platelet volume analysis for differential diagnosis of thrombocytosis","volume":"39","author":"van der Lelie","year":"1986","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1056\/NEJM197809072991002","article-title":"Platelet function in essential thrombocythemia. Decreased epinephrine responsiveness associated with a deficiency of platelet \u03b1-adrenergic receptors","volume":"299","author":"Kaywin","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2005.12.031_bib31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0038-1650032","article-title":"Abnormal aggregation and increased size of platelets in myeloproliferative disorders","volume":"43","author":"Cortelazzo","year":"1980","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2005.12.031_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0308-2261(21)00376-3","article-title":"Thrombocytosis and thrombocythaemia","volume":"12","author":"Murphy","year":"1983","journal-title":"Clin. Haematol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1001\/archinte.1969.00300180007002","article-title":"Defective platelets in essential thrombocythemia","volume":"124","author":"Spaet","year":"1969","journal-title":"Arch. Int. Med."},{"key":"10.1016\/j.bcmd.2005.12.031_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/ajcp\/95.1.82","article-title":"Platelet aggregation in platelet rich plasma and whole blood in 120 patients with myeloproliferative disorders","volume":"95","author":"Balduini","year":"1991","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib35","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1046\/j.1365-2141.1999.01399.x","article-title":"Thrombosis and bleeding in myeloproliferative disorders: identification of at risk patients with whole blood platelet aggregation studies","volume":"105","author":"Manoharan","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib36","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1309\/K58EWK4HPD51U3BE","article-title":"Platelet dysfunction in primary thrombocythemia using the platelet function analyzer, PFA-100","volume":"123","author":"Cesar","year":"2005","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib37","first-page":"853","article-title":"Improvement of platelet aggregation abnormalities in thrombocytosis after thrombocytopheresis","volume":"108","author":"Fabris","year":"1981","journal-title":"Folia Haematol., Int. Mag. Klin. Morphol. Blutforsch."},{"key":"10.1016\/j.bcmd.2005.12.031_bib38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1096-8652(199601)51:1<79::AID-AJH13>3.0.CO;2-6","article-title":"Platelet activation and thrombosis: studies in a patient with essential thrombocythemia","volume":"51","author":"Nurden","year":"1996","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib39","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1055\/s-0038-1649916","article-title":"Increased thromboxane biosynthesis in essential thrombocythemia","volume":"74","author":"Rocca","year":"1995","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2005.12.031_bib40","series-title":"Molecular Basis of Chronic Myeloproliferative Disorders","first-page":"106","article-title":"Thrombotic complications in ET: the role of the analysis of the platelet proteome","author":"Petrides","year":"2004"},{"key":"10.1016\/j.bcmd.2005.12.031_bib41","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"JAK2 V617F mutation identifies a biologically distinct subtype of essential thrombocythaemia which resembles polycythemia vera","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2005.12.031_bib42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminhematol.2005.05.023","article-title":"Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils","volume":"42","author":"Falanga","year":"2005","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.bcmd.2005.12.031_bib43","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0049-3848(02)00354-7","article-title":"Markers of platelet activation and platelet leukocyte interaction in patients with myeloproliferative syndromes","volume":"108","author":"Villmow","year":"2002","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bcmd.2005.12.031_bib44","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/sj.leu.2401270","article-title":"Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients","volume":"13","author":"Besses","year":"1999","journal-title":"Leukemia"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997960600026X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997960600026X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:23:21Z","timestamp":1761049401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107997960600026X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S107997960600026X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2005.12.031","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombotic complications in essential thrombocythemia (ET): Clinical facts and biochemical riddles","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2005.12.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}